Fibronectin replacement in patients with fulminant hepatic failure

Area of Science:

• Hepatology
• Immunology
• Critical Care Medicine

Background:

• Fulminant hepatic failure (FHF) is associated with low plasma fibronectin levels.
• Cardiovascular disturbances in FHF resemble septic shock, potentially linked to microembolization.
• Low fibronectin may impair the reticuloendothelial system's function.

Purpose of the Study:

• To investigate the effect of fibronectin administration in patients with FHF.
• To assess the impact on plasma fibronectin levels and opsonic activity.
• To explore potential improvements in reticuloendothelial system function.

Main Methods:

• Six patients with FHF received a single injection of a fibronectin concentrate.
• Plasma immunoreactive fibronectin levels were measured before and after administration.
• In vitro plasma opsonic activity was assessed.
• Cardiopulmonary function and oxygen utilization were monitored.

Main Results:

• Plasma fibronectin levels significantly increased post-administration (53 to 295 µg/ml).
• In vitro plasma opsonic activity showed a significant increase (5.6% to 102% of control).
• No significant changes in cardiopulmonary function or oxygen utilization were observed.

Conclusions:

• Fibronectin administration effectively raises plasma fibronectin levels and enhances opsonic activity in FHF patients.
• The observed lack of cardiopulmonary changes might be due to Kupffer cell damage.
• Further research is needed to clarify the role of fibronectin in FHF pathophysiology and treatment.